Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit
Healthcare Companies Added to Russell Microcap Index: FTSE Russell announced that several healthcare firms, including Editas Medicine, Cassava Sciences, Ginkgo Bioworks, Butterfly Network, and Tonix Pharmaceuticals, will be added to the Russell Microcap Index effective June 27.
Healthcare Stocks Removed from Russell Microcap Index: The index will see the removal of Mannkind, Ocugen, Nektar Therapeutics, Atossa Therapeutics, and Cel-Sci from its listings.
Trade with 70% Backtested Accuracy
Analyst Views on SAVA
About SAVA
About the author
Cassava Technologies and AXON Networks Form Strategic Partnership
- Strategic Partnership Announcement: Cassava Technologies and AXON Networks unveiled their strategic partnership at the Counder Conference in Cape Town, aiming to co-develop Africa's first end-to-end Operator-as-a-Service (OaaS) platform to drive digital transformation through AI-driven network solutions.
- Infrastructure Enhancement: The OaaS platform will leverage Cassava's extensive 110,000 km fiber network to deliver secure, high-speed data infrastructure, significantly enhancing the agility and intelligence of mobile network operators and ISPs, thereby fostering economic growth and innovation.
- AI-Driven Digital Twin Technology: AXON's Digital Twin technology will transform networks into self-learning, self-optimizing systems, reducing operational complexity, accelerating service delivery, and ensuring resilient connectivity at scale, thus providing customers with more efficient service experiences.
- Market Potential Unleashed: This collaboration will not only provide a robust digital foundation for African businesses but also promote widespread AI adoption, helping enterprises gain competitive advantages in the global market and showcasing Africa's immense potential in the digital economy.
Cassava Sciences Faces Shareholder Rights Investigation by Halper Sadeh LLC
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Cassava Sciences, Inc. breached their fiduciary duties to shareholders, potentially impacting corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of Cassava stock may have the opportunity to seek corporate governance reforms, return of funds, or court-approved financial incentive awards, which could directly affect shareholder financial interests and company transparency.
- Importance of Participation: Shareholder involvement can help improve company policies and oversight mechanisms, thereby enhancing management efficiency and transparency, ultimately increasing shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide who have fallen victim to securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its capability in protecting investor rights.
Cassava Sciences Inc. Settles Securities Class Action for $31.25 Million
- Settlement Agreement: Cassava Sciences Inc. has reached a definitive agreement to settle a consolidated securities class action from 2021 by agreeing to pay $31.25 million to resolve all claims related to investors who purchased its common stock or options between September 14, 2020, and October 12, 2023, although the settlement does not include any admission of wrongdoing.
- Financial Implications: The company has fully reserved the $31.25 million settlement amount as a loss contingency in Q2 2025, which will directly impact its future financial condition and potentially affect investor confidence.
- Management Confidence: CEO Rick Barry stated that with this settlement, the company can focus its attention and resources on the continued development of simufilam as a potential treatment for TSC-related epilepsy, indicating a positive outlook during the transition.
- Stock Price Movement: Following the settlement announcement, Cassava's shares fell 1.26% to $2.35 in premarket trading, reflecting market caution regarding the settlement and the company's future developments.
Cassava Sciences Settles $31.25 Million Securities Class Action Litigation
- Settlement Agreement: Cassava Sciences has reached a definitive agreement to pay $31.25 million to resolve a securities class action lawsuit that has been ongoing since 2021, allowing the company to focus on the development of simufilam and enhance its competitive position in CNS disorder treatments.
- Legal Risk Mitigation: The settlement will release all claims related to the litigation without admitting any wrongdoing, which helps to reduce future legal risks and improve investor confidence in the company's operations.
- Financial Provisioning: Cassava fully reserved a loss contingency of $31.25 million in Q2 2025 to address the settlement, ensuring financial transparency and protecting shareholder interests amid ongoing litigation.
- R&D Focus: By resolving this legacy litigation, Cassava can redirect resources towards clinical research for simufilam, with plans for a Phase 2 proof-of-concept study targeting TSC-related epilepsy, further driving innovation in the biotechnology sector.
Cassava Sciences agrees to $31.25 million settlement in securities class action lawsuit
Settlement Announcement: Cassava Sciences has agreed to pay $31.25 million to settle a class action lawsuit in Texas over alleged violations of federal securities laws related to its lead asset, simufilam.
Trial Setback: The company faced a setback in November 2024 during a late-stage trial for simufilam, which is aimed at treating Alzheimer's disease.
No Admission of Wrongdoing: Cassava stated that the settlement does not imply any admission of fault or wrongdoing, and it has recorded a provision for the settlement in its Q2 2025 financials.
Regulatory Challenges: The company has also encountered regulatory hurdles, including a request from the FDA for additional data on the simufilam trial.
FDA Places Full Clinical Hold on Cassava's Simufilam Epilepsy Trial
FDA Clinical Hold: Cassava Sciences Inc. received a formal letter from the FDA placing a full clinical hold on its trial for simufilam, requiring additional pre-clinical data and protocol modifications before proceeding.
Delayed Clinical Trial: The company no longer anticipates starting a proof-of-concept clinical trial for simufilam in TSC-related epilepsy in the first half of 2026, with timing now dependent on FDA review outcomes.
Discontinuation of Alzheimer's Development: Cassava has halted the development of simufilam for Alzheimer's disease after the Phase 3 REFOCUS-ALZ study failed to meet key endpoints.
Stock Price Impact: Following these developments, Cassava Sciences' shares fell by 25.26%, trading at $2.13 at the time of publication.
Cassava Technologies and AXON Networks Form Strategic Partnership
- Strategic Partnership Announcement: Cassava Technologies and AXON Networks unveiled their strategic partnership at the Counder Conference in Cape Town, aiming to co-develop Africa's first end-to-end Operator-as-a-Service (OaaS) platform to drive digital transformation through AI-driven network solutions.
- Infrastructure Enhancement: The OaaS platform will leverage Cassava's extensive 110,000 km fiber network to deliver secure, high-speed data infrastructure, significantly enhancing the agility and intelligence of mobile network operators and ISPs, thereby fostering economic growth and innovation.
- AI-Driven Digital Twin Technology: AXON's Digital Twin technology will transform networks into self-learning, self-optimizing systems, reducing operational complexity, accelerating service delivery, and ensuring resilient connectivity at scale, thus providing customers with more efficient service experiences.
- Market Potential Unleashed: This collaboration will not only provide a robust digital foundation for African businesses but also promote widespread AI adoption, helping enterprises gain competitive advantages in the global market and showcasing Africa's immense potential in the digital economy.
Cassava Sciences Faces Shareholder Rights Investigation by Halper Sadeh LLC
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Cassava Sciences, Inc. breached their fiduciary duties to shareholders, potentially impacting corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of Cassava stock may have the opportunity to seek corporate governance reforms, return of funds, or court-approved financial incentive awards, which could directly affect shareholder financial interests and company transparency.
- Importance of Participation: Shareholder involvement can help improve company policies and oversight mechanisms, thereby enhancing management efficiency and transparency, ultimately increasing shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide who have fallen victim to securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its capability in protecting investor rights.
Cassava Sciences Inc. Settles Securities Class Action for $31.25 Million
- Settlement Agreement: Cassava Sciences Inc. has reached a definitive agreement to settle a consolidated securities class action from 2021 by agreeing to pay $31.25 million to resolve all claims related to investors who purchased its common stock or options between September 14, 2020, and October 12, 2023, although the settlement does not include any admission of wrongdoing.
- Financial Implications: The company has fully reserved the $31.25 million settlement amount as a loss contingency in Q2 2025, which will directly impact its future financial condition and potentially affect investor confidence.
- Management Confidence: CEO Rick Barry stated that with this settlement, the company can focus its attention and resources on the continued development of simufilam as a potential treatment for TSC-related epilepsy, indicating a positive outlook during the transition.
- Stock Price Movement: Following the settlement announcement, Cassava's shares fell 1.26% to $2.35 in premarket trading, reflecting market caution regarding the settlement and the company's future developments.
Cassava Sciences Settles $31.25 Million Securities Class Action Litigation
- Settlement Agreement: Cassava Sciences has reached a definitive agreement to pay $31.25 million to resolve a securities class action lawsuit that has been ongoing since 2021, allowing the company to focus on the development of simufilam and enhance its competitive position in CNS disorder treatments.
- Legal Risk Mitigation: The settlement will release all claims related to the litigation without admitting any wrongdoing, which helps to reduce future legal risks and improve investor confidence in the company's operations.
- Financial Provisioning: Cassava fully reserved a loss contingency of $31.25 million in Q2 2025 to address the settlement, ensuring financial transparency and protecting shareholder interests amid ongoing litigation.
- R&D Focus: By resolving this legacy litigation, Cassava can redirect resources towards clinical research for simufilam, with plans for a Phase 2 proof-of-concept study targeting TSC-related epilepsy, further driving innovation in the biotechnology sector.
Cassava Sciences agrees to $31.25 million settlement in securities class action lawsuit
Settlement Announcement: Cassava Sciences has agreed to pay $31.25 million to settle a class action lawsuit in Texas over alleged violations of federal securities laws related to its lead asset, simufilam.
Trial Setback: The company faced a setback in November 2024 during a late-stage trial for simufilam, which is aimed at treating Alzheimer's disease.
No Admission of Wrongdoing: Cassava stated that the settlement does not imply any admission of fault or wrongdoing, and it has recorded a provision for the settlement in its Q2 2025 financials.
Regulatory Challenges: The company has also encountered regulatory hurdles, including a request from the FDA for additional data on the simufilam trial.
FDA Places Full Clinical Hold on Cassava's Simufilam Epilepsy Trial
FDA Clinical Hold: Cassava Sciences Inc. received a formal letter from the FDA placing a full clinical hold on its trial for simufilam, requiring additional pre-clinical data and protocol modifications before proceeding.
Delayed Clinical Trial: The company no longer anticipates starting a proof-of-concept clinical trial for simufilam in TSC-related epilepsy in the first half of 2026, with timing now dependent on FDA review outcomes.
Discontinuation of Alzheimer's Development: Cassava has halted the development of simufilam for Alzheimer's disease after the Phase 3 REFOCUS-ALZ study failed to meet key endpoints.
Stock Price Impact: Following these developments, Cassava Sciences' shares fell by 25.26%, trading at $2.13 at the time of publication.
